A network meta-analysis of MASLD drugs at fibrosis stages F1-F3 put survodutide ↗ on top of every intervention it compared. The headline relative risk for resolving steatohepatitis without making fibrosis worse was 7.25 versus placebo at 6 mg/week, with a 95% confidence interval that ran from 2.07 to 25.36. The Journal of Translational Medicine paper ↗, online May 26, pulled in thirteen randomized trials with 3,871 patients on twelve drugs, then ranked them by a statistical summary (SUCRA) that scores each drug across all probability scenarios.
Survodutide 6 mg/week landed at SUCRA 92.0 percent. Translation: in 92 percent of simulated rankings the drug came out best. Tirzepatide ↗ 15 mg/week sat next at 89.9 percent (relative risk 6.00 versus placebo, confidence interval 1.91 to 18.89), with the 10 mg and 5 mg tirzepatide doses below it in dose order. Resmetirom, the THR-beta agonist that became the first FDA-approved MASH drug in 2024, ranked at the bottom of the active interventions, with the 100 mg/day dose at a relative risk of 3.07 (1.31 to 7.16) and the 80 mg/day dose at 2.56 (1.09 to 6.02). Emricasan, an old caspase inhibitor, sat at SUCRA 8.1 percent, last in the field.
The wide confidence interval on survodutide is the caveat that does most of the work. A relative risk of 7.25 with a lower bound of 2.07 means the drug is reliably better than placebo, but the true effect could be anywhere from "about twice as good as placebo" to "twenty-five times as good," and the network is borrowing evidence across trials that did not directly compare survodutide and tirzepatide head-to-head. The point estimate is the top of the ladder. The interval is wider than any other drug on the list. Both facts are part of the same number.
What changed between this network meta and the prior synthesis. The authors note that an earlier MASLD network meta did not break out specific doses, which made it impossible to apply to a population for a particular treatment regimen. This one separates 5, 10, and 15 mg tirzepatide and 80 versus 100 mg resmetirom, and the dose breakdown is what lets the ranking move. Tirzepatide 15 mg pushed the GIP/GLP-1 dual agonist into the same neighborhood as survodutide on this endpoint, and the resmetirom doses split into a tier of their own.
The mechanism story underneath the numbers is that adding glucagon receptor agonism on top of GLP-1 changes the liver-fat reduction profile in a way that pure GLP-1 alone, or GLP-1 plus GIP, does not. Survodutide ↗ is a peptide built for that combination, a dual GLP-1R/GCGR agonist that Boehringer Ingelheim runs as BI 456906 in partnership with Zealand. The companion class member running in Phase 2b at EASL this week, pemvidutide ↗, is also a GLP-1/glucagon dual agonist but is not in the meta-analysis because its readouts post-date the included trials. The next iteration of this meta will have to add it.
What this changes for someone working on peptides. The first FDA-approved MASH drug (resmetirom) is now bracketed below at least two peptide programs on a head-to-head efficacy ladder, even if the trial-level evidence backing the ladder still has wide intervals. The GLP-1/glucagon dual mechanism that survodutide and pemvidutide share has, on the most recent synthesis available, the largest reported effect size on the fibrosis-friendly NASH-resolution endpoint at the doses tested. The Phase 3 LIVERAGE program will decide whether the network estimate survives a direct comparison against placebo at scale. For now, the ranking is the news, and the confidence interval is the asterisk that has to travel with it.